Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Surged Today

By Joe Tenebruso - Jun 2, 2021 at 4:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech could play an important role in the battle against cancer and autoimmune diseases.

What happened

Shares of Sorrento Therapeutics (SRNE -15.87%) jumped 10.5% on Wednesday, as investors cheered two positive announcements from the biopharmaceutical company. 

So what

Sorrento said it completed its acquisition of ACEA Therapeutics for roughly $38 million, as well as up to $450 million in additional payments if certain regulatory approvals and sales goals are met. Sorrento praised the drugmaker's pipeline, which includes abivertinib, which has generated promising clinical trial results in lymphoma and non-small cell lung cancer. 

Abivertinib is also being evaluated in phase 2 clinical trials for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19. Sorrento said it expects to share the results from this trial by late September.

People are working in a lab.

Image source: Getty Images.

Separately, Sorrento announced that the Mexican government added Covi-Stix to its official list of rapid antigen tests approved for emergency use in the country. Sorrento's approximately 15-minute diagnostic test outperformed other COVID-19 tests for both sensitivity and specificity in studies conducted by Mexican health officials. 

The designation will now allow Sorrento to begin marketing Covi-Stix in Mexico. It could also help the biotech gain additional emergency use authorizations in other Latin American countries, according to management. 

Now what

Sorrento intends to begin new clinical trials for abivertinib for the treatment of other cancers and autoimmune diseases, including prostate cancer, leukemia, multiple sclerosis, and lupus. The company is also seeking a larger partner to help co-develop and market abivertinib globally. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$2.12 (-15.87%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.